ReviewFrontiers in pharmacology2024
Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cannabis Certifications for Severe Chronic and Intractable Pain: Geographic Patterns across Pennsylvania, USA.Medical cannabis and cannabinoidsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The therapeutic potential of medical cannabis has garnered significant attention in recent years, prompting an urgent need for a comprehensive understanding of its effectiveness across various health outcomes. This article presents an Evidence Map that systematically summarizes clinical evidence on the use of medical cannabis, including the health conditions it addresses, the interventions employed, and the resulting clinical outcomes. The objective is to map the effectiveness of medical cannabis in relation to a wide range of health outcomes. The systematic review process involved two independent, blinded literature researchers who screened the search output using Rayyan software. For studies deemed relevant, full texts were obtained to clarify inclusion or exclusion criteria, and any disagreements were resolved through group discussion. Out of 1,840 initial references, 279 potential studies were selected and read in full, resulting in the inclusion of 194 studies in this evidence map. The results highlight the use of various cannabis formulations, including those based on isolated cannabidiol (CBD). Seventy-one distinct health outcomes were identified in the systematic reviews, with the most reported outcomes being related to various types of pain and patient safety. Other frequently studied outcomes included appetite regulation, chemotherapy-induced nausea and vomiting, and muscle spasticity. Notably, 278 out of 489 descriptions of treatment effects for these health outcomes reported either "Positive" or "Potentially Positive" effects. When considering only high-quality systematic reviews, as evaluated by the AMSTAR 2 tool, 42 out of 67 descriptions of treatment effects for up to 20 health outcomes were classified as "Positive" or "Potentially Positive." These outcomes included pain, insomnia, seizures, anxiety, muscle spasticity, multiple sclerosis, urinary incontinence, anorexia, and patient safety. This evidence map provides a comprehensive overview of the current clinical evidence on medical cannabis, highlighting its potential therapeutic benefits across a range of health conditions and emphasizing the need for further high-quality research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.